Aim: To examine corneal hysteresis (CH) and corneal resistance factor (CRF) in normal and ectatic corneas. Methods: CH and CRF were measured using the Reichert Ocular Response Analyzer in patients with clinically diagnosed keratoconus (KC), forme fruste KC (FFKC) and normal eyes. Results: 21 eyes (13 patients) with clinically diagnosed KC and 30 eyes (18 patients) with FFKC were included in the study. Mean CH and CRF in FFKC did not differ from that in pachymetry-matched normal eyes. KC eyes had significantly lower CH and CRF than normal and FFKC eyes. Conclusion: A significant overlap in CH and CRF values among the 3 groups was evident. Our findings do not indicate a role for CH and CRF measurement as a single test to aid in the detection of early ectasia. It may be of use when used in conjunction with other parameters such as aberrometry. CH and CRF values may prove to be useful in monitoring ectasia progression.

Keywords:
Hysteresis, Corneal resistance factor, Ocular aberrations
1.
Holland DR, Maeda N, Hannush SB, Riveroll LH, Green MT, Klyce SD, Wilson SE: Unilateral keratoconus. Incidence and quantitative topographic analysis. Ophthalmology 1997;104:1409–1413.
2.
Auffarth GU, Wang L, Volcker HE: Keratoconus evaluation using the Orbscan Topography System. J Cataract Refract Surg 2000;26:222–228.
3.
Maguire LJ, Bourne WM: Corneal topography of early keratoconus. Am J Ophthalmol 1989;108:746–748.
4.
Rao SN, Raviv T, Majmudar PA, Epstein RJ: Role of Orbscan 11 in screening keratoconus suspects before refractive corneal surgery. Ophthalmology 2002;109:1642–1646.
5.
Gobbe M, Guillon M: Corneal wavefront aberration measurements to detect keratoconus patients. Cont Lens Anterior Eye 2005;28:57–66.
6.
Alio JL, Shabayek MH: Corneal higher order aberrations: a method to grade keratoconus. J Refract Surg 2006;22:539–545.
7.
Maeda N, Fujikado T, Kuroda T, Mihashi T, Hirohara Y, Nishida K, Watanabe H, Tano: Wavefront aberrations measured with Hartmann-Shack sensor in patients with keratoconus. Ophthalmology 2002;109:1996–2003.
8.
Barbero S, Marcos S, Merayo-Lloves J, Moreno-Barriuso E: Validation of the estimation of corneal aberrations from videokeratography in keratoconus. J Refract Surg 2002;18:263–270.
9.
Luce DA: Determining in vivo biomechanical properties of the cornea with an ocular response analyzer. J Cataract Refract Surg 2005;31:156–162.
10.
Shah S, Laiquzzaman M, Cunliffe I, Mantry S: The use of the Reichert Ocular Response Analyser to establish the relationship between ocular hysteresis, corneal resistance factor and central corneal thickness in normal eyes. Cont Lens Anterior Eye 2006;29:257–262.
11.
Buhren J, Kuhne C, Kohnen T: Defining subclinical keratoconus using corneal first surface higher-order aberrations. Am J Ophthalmol 2007;143:381–389.
12.
Kirwan C, O’Keefe M, Lanigan B: Corneal hysteresis and intraocular pressure measurement in children using the Reichert Ocular Response Analyzer. Am J Ophthalmol 2006;142:990–992.
13.
Kirwan C, O’Keefe M: Corneal hysteresis using the Reichert Ocular Response Analyzer – findings pre and post LASIK and LASEK. Acta Ophthalmol 2008;86:215–218.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.